Rezpegaldesleukin improved asthma control in patients with atopic dermatitis, with FDA Fast Track status granted.

Nektar Therapeutics presented new Phase 2b data from the REZOLVE-AD trial at the 2025 ACAAI meeting, showing that rezpegaldesleukin significantly improved asthma control in patients with moderate-to-severe atopic dermatitis and a history of asthma. Two dosing regimens reduced mean ACQ-5 scores at week 16 compared to placebo, with greater benefits in those with uncontrolled asthma. The drug also sustained improvements in skin outcomes through week 24, supporting a 24-week induction period. The FDA has granted Fast Track status for rezpegaldesleukin in both atopic dermatitis and severe alopecia areata. Top-line results for alopecia areata are expected in December 2025, with long-term data from the study due in early 2026.